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ABSTRACT: A series of derivatives of the 4,5-disubstituted class of 2-deoxystrept-
amine aminoglycoside antibiotics neomycin, paromomycin, and ribostamycin was
prepared and assayed for (i) their ability to inhibit protein synthesis by bacterial
ribosomes and by engineered bacterial ribosomes carrying eukaryotic decoding A
sites, (ii) antibacterial activity against wild type Gram negative and positive
pathogens, and (iii) overcoming resistance due to the presence of aminoacyl
transferases acting at the 2′-position. The presence of ﬁve suitably positioned residual
basic amino groups was found to be necessary for activity to be retained upon
removal or alkylation of the 2′-position amine. As alkylation of the 2′-amino group
overcomes the action of resistance determinants acting at that position and in
addition results in increased selectivity for the prokaryotic over eukaryotic ribosomes,
it constitutes an attractive modiﬁcation for introduction into next generation aminoglycosides. In the neomycin series, the
installation of small (formamide) or basic (glycinamide) amido groups on the 2′-amino group is tolerated.
KEYWORDS: aminoglycosides, multidrug-resistant infectious diseases, decoding A site, selectivity, synthesis
The increasing threat of multidrug-resistant infectiousdiseases demands continued development of new and
improved anti-infective agents.1−6 In this regard, aminoglyco-
sides (AGAs)7−11 are strong candidates for further development
because of their widespread availability, innate potency, and the
extensive knowledge base covering their mechanism of
action10,12,13 and chemistry.7,14−16 Together with the deep
understanding of the mechanism of resistance, this knowledge
base has long informed the structure-based design of new
generations of AGAs,17−24 as exempliﬁed by the recent
introduction of the semisynthetic AGA plazomicin 1 into
clinical practice.25,26 In addition to many aminoglycoside
modifying enzymes (AMEs),27−30 a second important and
growing mechanism of AGA resistance is the modiﬁcation of
G1405 in the drug binding pocket in the decoding A site of the
bacterial ribosome by the ribosomal methyl transferases
(RMTs).31 The action of the G1405 RMTs greatly diminishes
the activity of all members of the 4,6-disubstituted 2-
deoxystreptamine (DOS) class of AGAs, that is, all AGAs in
current clinical use including plazomicin,25,26,32 and is especially
problematic when the responsible genes are encoded on the
same plasmid as those for a metallocarbapenemase.31,33−35
Fortunately, DOS-type AGAs lacking a ring substitution at the 6-
position do not make direct contact with G1405 and are not
susceptible to the action of RMTs.36 Such AGAs include the 4,5-
disubstituted DOS class such as paromomycin 2 and neomycin
3, and the unusual monosubstituted DOS AGA apramycin
4,37−41 currently a clinical candidate for the treatment of
complicated urinary tract infections.42
Accordingly, we have focused our eﬀorts on the design and
development of semisynthetic AGAs in the 4,5-DOS class with
emphasis on modiﬁcation at the 4′- and 6′-positions of
paromomycin,43−46 as exempliﬁed by propylamycin 5 (4′-
deoxy-4′-propylparomomycin).47 In addition to thwarting the
action of several AMEs, we discovered that the introduction of
appropriate substituents to the 4′-position of paromomycin
disproportionately reduces aﬃnity for the drug binding site in
the eukaryotic ribosomes, cytoplasmic and mitochondrial,
thereby increasing target selectivity and reducing ototoxicity,
an important side eﬀect of AGA therapy,48−50 as borne out by in
vivo studies with guinea pigs.44,47 Stimulated by early
observations in the literature on the derivatization of the 2′-
position of paromomycin and neomycin directed at circum-
venting the action of the AAC(2′) class of aminoglycoside acetyl
transferase AMEs,51−53 we now turn our attention to and report
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here on the possibility of circumventing AME action in
conjunction with improvements in target selectivity by
modiﬁcation at the 2′-position of paromomycin 2, neomycin
3, and ribostamycin 6 (Figure 1).
■ RESULTS
Chemical Synthesis. By adapting a literature procedure for
the regioselective tetra-N-acetylation of paromomycin,51 treat-
ment of a solution of paromomycin 2 and neomycin B 3 free
bases in methanol containing 1N aqueous HCl with acetic
anhydride gave 1,3,2′′′,6′′′-tetra-N-acetyl paromomycin 7 and
1,3,6′,2′′′,6′′′-penta-N-acetyl neomycin 8 as the major products
in 41 and 39% isolated yields, respectively. Reductive amination
of both 7 and 8 with benzaldehyde, followed by a second
reductive amination with formaldehyde, and, in the case of the
neomycin derivative by peracetylation, aﬀorded the 2′-N-
benzyl-2′-N-methyl paromomycin and neomycin derivatives 9
and 10 in 48 and 62% yield, respectively (Scheme 1). Reductive
amination of 7 with acetaldehyde and propionaldehyde gave 11
and 12, whereas treatment of 8 with acetaldehyde and sodium
cyanoborohydride gave 13, all in moderate to good yield.
Hydrogenolysis of 9 and 10 over palladium hydroxide in
Figure 1. Some natural and semisynthetic aminoglycoside antibiotics.
Scheme 1. Synthesis of 2′-N-Alkyl Derivatives of Paromomycin and Neomycin
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methanol followed by heating to reﬂux with either aqueous
sodium hydroxide or barium hydroxide and then Sephadex
chromatography gave the 2′-N-methyl derivatives 14 and 15 of
paromomycin and neomycin, respectively. Simple heating of
11−13 with aqueous sodium or barium hydroxide followed by
Sephadex chromatography aﬀorded the known51 2′-N-ethyl
paromomycin derivative 16, the corresponding neomycin
derivative 18, and the 2′-N-propyl paromomycin derivative
17. All compounds in this and subsequent schemes were isolated
as their peracetate salts following lyophilization from aqueous
acetic acid.
Following the Farmitalia protocol,52 installation of a benzyl
carbamate on the amino group of 7 followed by peracetylation
gave 19 in 57% yield. Hydrogenolysis of 19 followed by
diazotization in aqueous acetic acid gave the known52
pseudotrisaccharide 20 in 52% yield. Glycosylation of acceptor
20 with donors 21 and 22, prepared as described in the
literature,54,55 with activation by N-iodosuccinimide and
trimethylsilyl triﬂate in a mixture of dichloromethane and
dimethylformamide, so as to obtain the axial glycosides
selectively,56 gave 23 and 24 in 46 and 29% yield, respectively.
Hydrogenolysis, heating to reﬂux in aqueous sodium hydroxide,
and Sephadex chromatography then gave the 2′-desamino-2′-
hydroxy paromomycin and neomycin derivatives 25 and 26,
respectively (Scheme 2). Glycosylation with donor 21 leading
directly to the glycoside 23 was considered preferable to the
more elaborate sequence employed previously in the prepara-
tion of 25 from 20 by the Farmitalia group who nevertheless
favored the use of DMF as solvent in their glycosylation
reaction.52 The cleavage of ring I from 19 by the nitrosylation
protocol conﬁrms the regioselectivity of the initial partial
acetylation of 2 giving 7 (Scheme 1) and of all subsequent
derivatives of it.
Formylation of 8 with formic acetic anhydride followed by
acetylation gave the 2′-N-formyl neomycin derivative 27. This
was converted by reaction with phosphorus oxychloride and
triethylamine to the corresponding isocyanate, which without
characterization was subject to the Barton deamination
reaction57−59 using tris(trimethylsilyl)silane60 in place of the
original tributyltin hydride, to aﬀord the 2′-desamino derivative
28 in 44% yield for the two steps. Hydrolysis with hot barium
hydroxide then aﬀorded 29 in the standard manner (Scheme 3).
No attempt was made to prepare the corresponding 2′-
desamino paromomycin derivative in view of the modest
antibacterial activity of the 2′-desamino-2′-hydroxy paromomy-
cin derivative 25.
Turning to the preparation of 2′-N-acyl derivatives, neomycin
B 3 was treated with acetic anhydride in the presence of HCl to
give crude 8, which was subjected to reaction with imidazole
sulfonyl azide61−64 and potassium carbonate in the presence of
copper sulfate to give the corresponding 2′-azido derivative.
Without isolation, and adopting the Grieco protocol for
acetamide cleavage,65 this compound was heated to reﬂux in
tetrahydrofuran with Boc2O andDMAP, followed by acetylation
Scheme 2. Synthesis of 2′-Desamino-2′-hydroxy Paromomycin and Neomycin Derivatives
Scheme 3. Synthesis of 2′-Desamino Neomycin
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with acetic anhydride in pyridine to give 30 in 13% overall yield
for the four steps from 3 (Scheme 4). Treatment with sodium
methoxide in methanol followed by Staudinger reduction of the
azide with trimethylphosphine66 then aﬀorded a 2′-amine 31
Scheme 4. Synthesis of Neomycin 2′-Amides
Scheme 5. Synthesis of Ribostamycin Derivatives 41, 42, and 46
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suitable for installation of various amides. Treatment of 31 with
formic acetic anhydride or acetic anhydride in pyridine followed
by aqueous methanolic sodium carbonate then gave amides 32
and 33 in 78 and 88% yield, respectively. Coupling of 31 with
azidoacetic acid67 by means of EDC and HOBt gave the azido
acetamide 34 in 68% yield. Finally, stirring of 32 and 33with wet
triﬂuoroacetic acid in the presence of anisole, followed by
sephadex chromatography and lyophilization from acetic acid
gave the 2′-N-formamide 35, and an authentic sample of the
acetamide 36 in 42, and 81% yields, respectively. In the case of
the glycinamide 37, isolated in 48% yield, the removal of the
carbamate groups was preceded by reduction of the azide
(Scheme 4). It is of interest, although not inconsistent with the
literature,68−70 that the formamide 35 exists in D2O solution as
an unassigned 7:3 mixture of rotamers.
In the ribostamycin series, the parent 6 was regioselectively
protected as the 1,3,6′-tris(benzyloxycarbamate) 38 by treat-
ment with N-(benzyloxycarbonyloxy)-5-norborene-endo-2,3-
dicarboximide (NBD)71 in the presence of sodium carbonate
in 36% yield. Sequential reductive amination with benzaldehyde
and then with formaldehyde gave the 2′-N-benzyl-2′-N-methyl
derivative 39 in 24% yield, while parallel treatment with
acetaldehyde and sodium cyanoborohydride gave the 2′-N-ethyl
derivative 40 in 44% yield. Hydrogenolysis of 39 and 40 over
palladium hydroxide then aﬀorded 2′-N-methyl and 2′-N-ethyl
ribostamycin, 41 and 42, in 26 and 23% yield, respectively
(Scheme 5). Reaction of 38 with formic acetic anhydride and
pyridine provided the 2′-formamide 43 in 59%, which was
converted to the peracetate 44 in 75% yield in the standard
manner. Dehydration of 44 with phosphorusoxy chloride and
triethylamine aﬀorded the corresponding 2′-isonitrile, which
was subjected to tris(trimethylsilyl)silane and AIBN in hot
toluene to give the 2′-desamino derivative 45 in 66% yield for
the two steps. Deprotection with sodiummethoxide inmethanol
followed by hydrogenloysis then aﬀorded 2′-desamino
ribostamycin 46 in 61% yield.
To prepare 2′-desamino-2′-hydroxy ribostamycin derivatives,
we again took an approach based on glycosylation of a 2-
deoxystreptamine derivative. Thus, adapting Hanessian’s
protocol for the degradation of rings I and IV,72 the perazido
paromomycin derivative 4773 was treated with periodic acid
followed by triethylamine to aﬀord the 5-O-ribosyl-2-deoxy-
streptamine derivative 48 in 23% yield (Scheme 6). Installation
of a trityl group on the primary alcohol to give 49 in 52% was
followed by conversion of the cis-diol to the corresponding
acetonide 50 in 95% yield with 2,2-dimethoxypropane under
catalysis by camphor-10-sufonic acid. Treatment of 50 with tert-
butyldimethylsilyl triﬂate in the presence of 2,6-lutidine gave a
single monosilyl ether 51 in 82% yield. Notwithstanding the
literature precedent for the regioselective monofunctionaliza-
tion of 50-like diols at the 6-position,74 51 was converted to the
crystalline derivative 52 in 60% yield by Staudinger reduction of
the azides followed by amide formation, whose structures were
conﬁrmed by X-ray crystallography (Supporting Information,
Figure S1, CCDC 1908319). The glycosyl acceptor 51 was
converted to the α-glycoside 55 in 47% yield by means of
reaction with sulfoxide 53 (Supporting Information) on
activation with triﬂic anhydride. Similarly, glycosylation of 51
with sulfoxide 54 (Supporting Information) gave the α-
glycoside 56 in 65% yield. Treatment of 55 and 56 with
tetrabutylammonium ﬂuoride and then acetic acid aﬀording the
triols 57 and 58, both in 44% yield, was followed by Staudinger
reaction and hydrogenolysis to give 2′-desamino-2′-hydroxy
ribostamycin 59 and the ribostamycin regioisomer 60 in 51 and
40% yields, respectively (Scheme 6).
Activity and Selectivity at the Target Level. All
compounds were studied for their ability to inhibit protein
synthesis in a series of cell-free translation assays as described
previously.43 These assays employed wild-type bacterial
Scheme 6. Synthesis of Ribostamycin Derivatives 59 and 60
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Mycobacterium smegmatis ribosomes and humanized hybrid M.
smegmatis ribosomes carrying complete eukaryotic decoding A
sites, that is, the crystallographically characterized drug binding
pocket (Figure 3),36,75 from human mitochondrial ribosomes
(Mit 13), A1555G mutant mitochondrial ribosomes (A1555),
and human cytoplasmic ribosomes (Cyt 14) (Figure 2 andTable
1).76 This model system, developed in our laboratories, was
previously employed to identify the mitoribosome as target in
aminoglycoside ototoxicity,77 to study the mechanisms of
mutant rRNA-associated deafness,78 and to rationalize amino-
glycoside activity against protozoa.79 In the series of experiments
reported in Table 1, inhibition of the mitochondrial ribosome,
together with slow clearance from the inner ear, is thought to be
the root cause of AGA-induced ototoxicity; the hyper-
susceptibility to AGA-induced ototoxicity found in a subset of
the population arises from the presence of the A1555Gmutation
in the mitochondrial decoding A site.77,78,80,81 Inhibition of the
human cytoplasmic ribosome on the other hand is expected to
result in more systemic toxicity.
As shown in Table 1, 2′-N-methylation and ethylation have
little to no eﬀect on the ability of paromomycin or neomycin to
inhibit translation by the bacterial ribosome. Even 2′-N-
propylation has a minimal eﬀect as demonstrated with the
paromomycin derivative 17. The eﬀects of these 2′-N-
alkylations on translation by the mitochondrial and cytoplasmic
hybrid ribosomes are minimal for paromomycin but result in
signiﬁcant increases in selectivity for neomycin. In addition,
these modiﬁcations have a marked eﬀect on A1555G mutant
mitochondrial ribosomes resulting in increases in selectivity of
between 3- and 10-fold. Theminimal loss of inhibitory activity of
2′-N-ethyl paromomycin for the bacterial ribosome is consistent
with the limited reduction in antibacterial activity observed
previously for this modiﬁcation.51 In contrast to the minimal
inﬂuence of 2′-N-alkylation in the paromomycin and neomycin
series, the comparable 2′-N-alkylated ribostamycin derivatives
41 and 42 were found to be 10-fold less active than the parent
against the bacterial ribosome. In view of the low antibacterio-
ribosomal activity of 41 and 42 and all subsequent ribostamycin
derivatives, the activity of ribostamycin compounds against the
eukaryotic ribosomes was not investigated.
Substitution of a hydroxyl group for an amino group at the 2′-
position has minimal inﬂuence on antiribosomal activity in the
neomycin series (analogue 26), consistent with the antibacterial
activity reported for this compound previously.52 Notably, a
signiﬁcant increase in selectivity for all eukaryotic decoding sites
Figure 2. Decoding A sites of prokaryotic and eukaryotic ribosomes.
The bacterial AGA binding pocket is boxed. The bacterial numbering
scheme is illustrated for the AGA binding pocket. Changes from the
bacterial ribosome binding pocket are colored green. The A1555G
mutant conferring hypersusceptibility to AGA ototoxicity is colored
red.
Table 1. Antiribosomal Activities (IC50,μM) and Selectivities
a
substituent IC50, μM selectivity
compound 6′ 2′ basic amino groups bacterial Mit13 A1555G Cyt14 Mit13 A1555G Cyt14
Neomycin Series
3 NH2 NH2 6 0.04 4.3 0.4 36 108 10 900
15 NH2 NHMe 6 0.01 4.7 1.1 37 470 110 3700
18 NH2 NHEt 6 0.02 11 1.6 43 550 80 2150
26 NH2 OH 5 0.03 36 2.9 108 1200 97 3600
29 NH2 H 5 0.03 22 0.9 85 773 30 2833
35 NH2 NHCHO 5 0.12 54 13 127 450 108 1058
36 NH2 NHAc 5 5.3 93 28 147 18 5.3 28
37 NH2 NHglycyl 5 0.16 11 1.2 25 69 8 156
Paromomycin Series
2 OH NH2 5 0.04 142 12 31 3550 300 775
14 OH NHMe 4 0.05 150 54 60 3000 1080 1200
16 OH NHEt 5 0.05 220 84 43 4400 1680 860
17 OH NHPr 5 0.07 223 58 32 3186 829 457
25 OH OH 4 2.2 662 313 446 301 142 203
Ribostamycin Series
6 NH2 NH2 4 0.10
41 NH2 NHMe 4 1.13
42 NH2 NHEt 1.93
59 NH2 OH 3 2.66
46 NH2 H 3 9.93
60b NH2 OH 4 >20
aSelectivities are obtained by dividing the eukaryotic by the bacterial values. bCompound 60 is additionally modiﬁed at the 3′-position by
replacement of the hydroxyl group by an amino group.
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(mitochondrial, A1555G, and cytosolic) is achieved by the 2′-
hydroxyl modiﬁcation. However, the identical substitution is
detrimental for both paromomycin and ribostamycin as
evidenced by the corresponding paromomycin and ribostamy-
cin analogues 25 and 59. The high activity of 26 suggested that
further such modiﬁcations would be tolerated in the neomycin
series, as was borne out by the 2′-desamino neomycin derivative
29, which again displays increased across the board selectivity
compared to the parent. The substantially reduced activity of 2′-
desamino-2′-hydroxy paromomycin 25 and of 2′-desaminor-
ibostamycin 46 discouraged us from making any further
modiﬁcations to the 2′-position of paromomycin and
ribostamycin that result in loss of the basic amine. In an attempt
to remove the 2′-amino group without a change in the number
of basic amines present, ribostamycin was converted to the
regioisomer 60 in which the 2′-amino group has been
substituted by an hydroxyl group, while the inverse modiﬁcation
was aﬀected at the 3′-position. Unfortunately, this modiﬁcation
was associated with a substantial loss of activity.
Table 2. Antibacterial Activities (MIC, μg/mL)a
substituent MRSA E. coli K. pneu E. cloa A. baum
compound 6′ 2′ AG038 AG001 AG003 AG215 AG290 AG225
Neomycin Series
3 NH2 NH2 0.5 1 1 0.25−0.5 1 1−2
15 NH2 NHMe 0.5 2 1 0.5 0.5−1 1
18 NH2 NHEt 0.5 1−2 1 0.5 0.5−1 1
26 NH2 OH 2 2−4 2−4 0.5 1 1
29 NH2 H 1 2 1−2 0.5 1 1
35 NH2 NHCHO 2−4 4−8 4−8 1−2 2 2
36 NH2 NHAc >128 >128 >128
37 NH2 NHglycyl 4 16 32
Paromomycin Series
2 OH NH2 4 2−4 4−8 1 2 2
16 OH NHEt 8 16 16
14 OH NHMe 8 8 16
17 OH NHPr 8−16 16 16
25 OH OH 64−128 >128 >128
Ribostamycin Series
6 NH2 NH2 4 4−8 4−8 2 4 4
41 NH2 NHMe 64−128 64−128 64
42 NH2 NHEt >128 128 128
59 NH2 OH >128 >128 >128
46 NH2 H ≥256
60b NH2 OH >128 >128 >128
aAll values were determined in duplicate using 2-fold dilution series. bCompound 60 is additionally modiﬁed at the 3′-position by replacement of
the hydroxyl group by an amino group.
Table 3. Antibacterial Activities Against E. coli Strains with Acquired AAC(2′) Resistance and Mycobacteria with Intrinsic
AAC(2′) Resistance (MIC, μg/mL)a
substituent E. coli AG001 E. coli AG106 E. coli pH434 M. abscessus ATCC 19977 (AAC2′) ratio M. abscessus wt/E. coli wt
compound 6′ 2′ wt AAC(2′)-1a AAC(2′)-1b wt
Neomycin Series
3 NH2 NH2 1 16 >64 16 16
15 NH2 NHMe 2 2.0 2−4 0.25 0.125
18 NH2 NHEt 1−2 1 2 0.25 0.125−0.25
26 NH2 OH 2−4 2 4 2 0.5−1.0
29 NH2 H 2 2 4 2 1
35 NH2 NHCHO 4−8 8 8−16
37 NH2 NHglycyl 16 16−32
Paromomycin Series
2 OH NH2 2−4 >64 >64 8 2−4
14 OH NHMe 8 8 8 16 2
16 OH NHEt 16 8 32 2
17 OH NHPr 16 8 32 2
Ribostamycin Series
6 NH2 NH2 4−8 128 >128
plazomicin 0.5−1 8−16 8
amikacin (2′OH) 2 2 2
aAll values were determined in duplicate using 2-fold dilution series.
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Turning to the installation of amides at the 2′-position, and
restricting ourselves to the neomycin series, formylation giving
the neomycin derivative 35 resulted in little loss of activity
against the bacterial ribosome coupled with a substantial
increase in selectivity for the mitochondrial and mutant
mitochondrial ribosomes. This is in contrast to 2′-N-acetylation,
the modiﬁcation introduced by the AAC(2′) family of AMEs,
which led to a greater than 100-fold loss in activity in derivative
36. The negative inﬂuence of the 2′-N-acetyl modiﬁcation on
activity can be largely overcome by its coupling with the
reinstallation of a basic amine as in the 2′-N-glycyl neomycin
derivative 37, which shows only a 4-fold loss of activity against
the bacterial ribosome compared to the parent. However, this
modiﬁcation comes with a substantial loss in selectivity with
regard to the cytoplasmic ribosome. These observations on the
inﬂuence of amide formation at the 2′-position are consistent
with the prior literature describing other 2′-amides. Thus, it has
been reported that the 2′-N-glycinamide derivatives of simple
aminoalkyl 2,6-diamino-α-D-glucopyranosides, and of fortimicin
B, retain antibacterial activity as does 2′-formamido sisomi-
cin.82−84
Antibacterial Activity in the Absence and Presence of
Aminoglycoside Modifying Enzymes. The antibacterial
activities displayed by the various paromomycin, neomycin, and
ribostamycin derivatives against clinical strains of the Gram-
positive methicillin-resistant Staphylococcus aureus (MRSA) and
the Gram-negative Escherichia coli (Table 2) were consistent
with their ability to inhibit bacterial protein synthesis in the
translation assays (Table 1). The more potent compounds were
also screened for activity against a single wild-type clinical strain
each of the ESKAPE pathogens, Klebsiella pneumoniae, Enter-
obacter cloacae, and Acinetobacter baumannii, with MICs
determined to be ≤4 μg/mL (Table 2).
As the 2′-amino group is the target for acetylation by the
AAC(2′) class of AMEs, the more active compounds were
screened for activity against two clinical strains of E. coli carrying
diﬀerent isoforms of AAC(2′) (Table 3). The presence of either
of these AAC(2′) isoforms greatly abrogates the activity of both
paromomycin and neomycin, consistent with the minimal
activity of authentic 2′-N-acetyl neomycin 36. In contrast, 2′-N-
methylation, ethylation, and propylation, compounds 14−18,
maintains activity in the presence of AAC(2′). Similarly, the 2′-
desamino-2′-hydroxy and 2′-desamino modiﬁcations in the
neomycin series, compounds 26 and 29, resist the AAC(2′) class
of AMEs in E. coli, as does the 2′-N-formyl modiﬁcation
displayed in compound 35. Plazomicin, obtained by an
improved synthesis,32 and amikacin, one carrying a 2′-amino
group and the other a 2′-hydroxy group, served as controls for
the AAC(2′) AMEs in E. coli.
Mycobacterium abscessus is a growing threat in hospitalized
patients with chronic pulmonary disease or cystic ﬁbrosis.85 The
innate AGA susceptibility of M. abscessus is determined by the
presence of a functional AAC(2′) AME,86 prompting us to test
the more active compounds against the M. abscessus reference
strain ATCC 19977. To illustrate the eﬀect of the mycobacterial
AAC2′ on compound activity, we also calculated the ratio ofM.
abscessus wt (AAC2′ present) versus E. coli wt (no AAC2′
present). Inherently, the mycobacterial AAC2′ shows little
activity toward paromomycin but signiﬁcantly reduces the
antimycobacterial activity of neomycin. In line with expectation,
the 2′-N-alkyl derivatives of paromomycin 14, 16, and 17 did
not show any diﬀerence compared to the parent; however, the
same modiﬁcations in the neomycin series, as in compounds 15
and 18, were highly eﬃcacious resulting in a 64-fold reduction in
MIC values (Table 3). The 2′-desamino-2′-hydroxy and 2′-
desamino derivatives 26 and 29 of neomycin also showed much
greater activity against M. abscessus than the parent.
Finally, selected compounds were screened for activity in the
presence of AAC(3), AAC(6′), ANT(4′,4′′), and APH(3′). As
expected, none of the modiﬁcations investigated was eﬀective at
suppressing the activity of these AMEs.
■ DISCUSSION
Classically, the activity of AGAs is considered to be correlated to
the number of basic amino groups87 and so, following
protonation at physiological pH, to the degree of electrostatic
attraction with the negatively charged drug binding pocket.88,89
The electrostatic component of the binding energy is
supplemented by a number of direct and water-mediated
hydrogen bonding contacts and other directional intermolecular
noncovalent interactions between the drug and the binding
pocket (Figure 3).27,75,87,90−92 The partitioning of the
contribution of an individual protonated amine to the binding
energy between electrostatic and directed components neces-
sarily varies with the location of the amine in the AGA. Thus,
while the amines of rings I and II of the 4,5-AGAs are involved in
multiple H-bonding interactions with the drug-binding pocket,
those of ring IV do so to a lesser extent (Figure 3). Indeed, it has
been suggested that ring IV serves simply as a concentration of
positive charge that makes a strong electrostatic contribution to
the binding energy.93 Finally, intramolecular conformation-
restricting noncovalent interactions within the body of the drug
itself have also been suggested to be an important component of
the binding energy.94 Among the hydrogen bonding interactions
between rings I and III of the 4,5-AGAs, speciﬁcally those
between the protonated 2′-amino group and O4′′ or O5′′ of the
ribofuranosyl moiety (Figure 3)75,95 are featured prominently.
On the basis of these interactions, Hermann and co-workers
prepared the conformationally restricted paromomycin and
neomycin analogues 61 and 62 and studied their binding to the
bacterial decoding A site.96,97 Contemporaneously, and with a
Figure 3. Schematic of the crystallographically determined interactions
of neomycin 3 (X = NH2
+) and paromomycin 2 (X = O) with the AGA
binding pocket. Ribostamycin 6 (X = NH2
+) binds identically but lacks
ring IV.
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view to exploiting the diﬀering conformations of AGAs bound to
the decoding A site and that of the ANT(4′,4′′) AMEs, Asensio
and co-workers prepared 62 and the higher homologue 63.98,99
Other workers have prepared complex aminoglycosides by
ribofuranosylation of the 5-OH in the 4,6-AGAs to take
advantage of this intramolecular interaction and other
contacts.100,101 Unfortunately, each of 61−63 showed reduced
aﬃnity for decoding A site models and reduced antibacterial
activity, the latter in common with an earlier conformationally
restricted analogue 64 of the ribostamycin isomer xylostacin.102
The pattern of antibacterioribosomal activity (Table 1) and
antibacterial activity (Table 2) of the present series of
compounds, together with the reduced activity of 61−63,
provides the opportunity to examine the interplay between
electrostatic and hydrogen bonding interactions in greater detail.
The parity in the ability of neomycin and its analogues 26 and 29
lacking the 2′-amino group to inhibit the function of the
bacterial ribosome (Table 1) and the growth of wild-type Gram-
negative pathogens (Table 2) indicates that the presence of ﬁve
appropriately located protonated amino groups provides
suﬃcient electrostatic attraction with the negatively charged
ribosome to overcome the absence of the 2′-amino group for
this scaﬀold. For paramomycin and ribostamycin on the other
hand, with only ﬁve and four such basic amino groups,
respectively, the reduction in the electrostatic component
conferred by removal of the 2′-amino group is critical, as
borne out by the reduced activity of 2′-desamino-2′-hydroxy
paromomycin 25 with its four protonated amino groups and by
the ribostamycin analogues 46 and 59, both with only three
protonated amino groups (Tables 1 and 2). Compensating for
the loss of C(2′)NH2 in 59 by reintroducing an amino group at
the 3′ position, resulting in compound 60, did not restore
activity. This indicates that in the ribostamycin series, with only
four basic amino groups, electrostatic attraction alone is not
suﬃcient for activity but must be complemented by location of
one of these groups at the 2′-position.
Alkylation of N2′ is tolerated when the molecule possesses
ﬁve or more suitably placed basic amines as is clear from the
activity of the neomycin and paromomycin analogs 14, 15, 16,
17, and 18 (Tables 1 and 3). The loss of activity observed for the
2′-N-alkylated ribostamycin analogues 41 and 42 on the other
hand indicates that even the correct placement of four basic
amino groups is insuﬃcient to compensate for the destabilizing
eﬀect of the alkyl groups. The retention of activity of 14, 15, 16,
17, and 18 contrasts with the reduced activity of the cyclic (2′-
N-alkylated) neomycin and paromomycin derivatives 61−63.
Cyclization of the 2′-amine onto the 5′′-position was reported to
result in a reduction in basicity of the 2′-amine in 61 and 62 by
∼1.5 pKa units. This reduction in pKa is most likely due to the
inductively electron-withdrawing O4′′ ribosyl ring oxygen,
which is β- to N2′ in 61 and 62,103 albeit the authors suggested
steric inhibition of solvation of the protonated amino group as
the cause.96,97,104 Whatever the underlying reason for the
reduction in basicity, aﬃnity for the ribosome was restored
under more acidic conditions, illustrating the importance of
protonation of N2′ in overcoming the negative eﬀect of the
cyclic modiﬁcation. Simple alkylation, as in 14, 15, 16, 17, and
18, on the other hand is expected to increase the basicity of N2′
consistent with their high levels of activity.103 The homologue
63 of 62 lacks the basicity-reducing vicinal relationship between
N2′ and O4′′ present in 61 and 62 but also shows a signiﬁcant
reduction in antibacterial activity and aﬃnity for a decoding A
site model.99 This suggests that the diminished activity of 61−
63 is at least in part due to other factors such as the loss of a
crystallographically observed (Figure 3)75 hydrogen bond from
5′′−OH in the parent to N7 of G1491 at the bottom of the
binding site.96−99 Overall, in the absence of cyclic constraints,
the presence of a basic amino group at the 2′-position of the 4,5-
AGAs is not necessary provided ﬁve other appropriately located
basic amino groups are present in the molecule. When a 4,5-
series AGA contains only four basic amino groups, one of them
must be at the 2′-position. Alkylation of the 2′-amino group is
tolerated in the absence of cyclic constraints provided there are a
minimum of ﬁve basic amino groups in the molecule.
With regard to the 2′-N-acyl derivatives of neomycin, the loss
of activity observed with the acetamide 36 was anticipated in
view of the well-known ability of the AAC(2′) AMEs to
signiﬁcantly reduce the activity of AGAs (Table 2). In view of
the high levels of activity retained by neomycin derivatives 26
and 29, both of which lack a basic nitrogen at the 2′-position, the
loss of activity due to 2′-acetamide formation cannot result from
a reduction in electrostatic binding energy in neomycin. The loss
of activity on acetamide formation can also not be due to the
inclusion of a hydrophobic methyl group, as simple 2′-N-
alkylation is well tolerated in both paromomycin and neomycin.
By a process of elimination, the detrimental eﬀect of the 2′-
acetamido group in the neomycin series must arise either from a
steric interaction or an unfavorable electrostatic interaction
involving the amide carbonyl group. The steric component of
this interaction is more important for the 2′-acetamide than for
the 2′-N-alkyl derivatives because of the rigid nature of the
amide function and its well-known orientation with respect to
the pyranose ring in all 2-deoxy-2-acetamido glucopyranose
derivatives.69 Further, it results mainly from the presence of the
acetamide methyl group as the corresponding formamide 36 is
considerably more active. In addition to its smaller size, the
formamide 36 is also capable of avoiding any unfavorable
electrostatic interaction by population of the cis- rather than the
trans-rotamer.70 Finally, the unfavorable interaction in the
acetamide is not so large as to prevent docking of the drug into
the binding site, as it can be partially overcome by the
introduction of a further basic amino group as in the glycinamide
37.
■ CONCLUSION
Extensive structure activity relationships (SAR) have been
provided, resulting from modiﬁcation of the 2′-position by
deletion, replacement by a hydroxy group, alkylation, and in part
acylation of the AGAs neomycin, paromomycin, and ribosta-
mycin. This SAR leads to a series of conclusions on the inﬂuence
of modiﬁcation at this position on ribosomal aﬃnity and
antibacterial activity. Thus, the presence of a basic amino group
at the 2′-position of the 4,5-AGAs is not essential for activity
provided ﬁve other suitably placed basic amines are present in
the molecule. In contrast, a basic amino group is required at the
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2′-position when a 4,5-series AGA contains only four such basic
amines. With ﬁve correctly placed basic amino groups present,
alkylation of the 2′-amine is tolerated. Most notably, in
paromomycin and in particular neomycin modiﬁcation of the
2′-amino group also results in a gain in selectivity for the
bacterial over the eukaryotic ribosomes, thereby providing an
attractive means of both overcoming resistance due to the
presence of AAC(2′)-type resistance determinants and increas-
ing ribosomal target selectivity by a single modiﬁcation.
Finally, the changes in selectivity between the prokaryotic and
the diﬀerent eukaryotic ribosomes occasioned by the various
modiﬁcations introduced at the 2′-position (Table 1)
presumably arise by indirect eﬀects as the 2′-amine makes no
direct contact with the drug binding pocket (Figure 3). These
diﬀerential eﬀects likely arise from interactions of the AGAs with
the ribosomal base 1491, which is G in the bacterial ribosomes
and A or C in the humanized ribosomes (Figure 2). Thus,
modiﬁcation of the 2′-substituent necessarily aﬀects the CH−π
interaction of the 4′−C−H bond with the base 1491 and,
because of the H-bond network, the H-bond of the 5′′-hydroxyl
group with the same base (Figure 3), both in a base-dependent
manner.
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(2019) Design, Multigram Synthesis, and in Vitro and in Vivo
Evaluation of Propylamycin: A Semisynthetic 4,5-Deoxystreptamine
Class Aminoglycoside for the Treatment of Drug-Resistant Enter-
obacteriaceae and Other Gram-Negative Pathogens. J. Am. Chem. Soc.
141, 5051−5061.
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